Critical appraisal of the potential use of cannabinoids in cancer management

Cancer Management and Research

Volumn 5, Issue 1, 2013, Pages 301-313

  Cridge, Belinda J ^a   Rosengren, Rhonda J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cancer; Cannabinoid; Endocannabinoid; JWH 133; Tetrahydrocannabinol; WIN 55,212 2

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOL; CERAMIDE; DELTA8 TETRAHYDROCANNABINOL; DEXANABINOL; DRONABINOL; LIPID; METHANANDAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; RAF PROTEIN; RIMONABANT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN;

ANALGESIC ACTIVITY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; APPETITE; ATAXIA; AUTOPHAGY; BREAST CANCER; BREAST TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CANCER THERAPY; COGNITIVE DEFECT; COORDINATION DISORDER; DRUG ANTAGONISM; DRUG DEGRADATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENDOTHELIUM CELL; GLIOMA CELL; HALLUCINATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LIVER CANCER; LUNG CANCER; MELANOMA; MEMORY DISORDER; METASTASIS INHIBITION; MOOD DISORDER; MOTOR DYSFUNCTION; NONHUMAN; PROSTATE CANCER; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TUMOR INVASION;

EID: 84883341895     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S36105     Document Type: Review

References (140)

1. Alexander A, Smith PF, Rosengren RJ. Cannabinoids in the treatment of cancer. Cancer Lett. 2009;285(1):6-12.
2. Cameron L, Williams J. Cannabis, alcohol and cigarettes: substitutes or complements? Econ Rec. 2001;77(236):19-34.
3. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86(8):1646-1647.
4. Devane W, Hanus L, Breuer A, etal. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258(5090):1946-1949.
5. Console-Bram L, Marcu J, Abood ME. Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacology Biol Psychiatry. 2012;38(1):4-15.
6. Piomelli D. Arachidonic acid in cell signaling. Curr Opin Cell Biol. 1993;5(2):274-280.
7. Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol. 1998;359(1):1-18.
8. Maccarrone M, Finazzi-Agrò A. Endocannabinoids and their actions. Vitam Horm. 2002;65:225-255.
9. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605-613.
10. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561-564.
11. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61-65.
12. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147 Suppl 1:S163-S171.
13. Guzmán M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003;3(10):745-755.
14. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res. 2008;68(2): 339-342.
15. Lange JH, Kruse CG. Recent advances in CB1 cannabinoid receptor antagonists. Curr Opin Drug Discov Devel. 2004;7(4):498-506.
16. Bergman J, Delatte MS, Paronis CA, Vemuri K, Thakur GA, Makriyannis A. Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiol Behav. 2008;93(4-5):666-670.
17. Ross RA, Brockie HC, Stevenson LA, etal. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol. 1999;126(3):665-672.
18. McPartland JM, Glass M, Pertwee RG. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol. 2007;152(5):583-593.
19. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol. 2007;152(5): 567-575.
20. Pertwee RG, Howlett AC, Abood ME, etal. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev. 2010;62(4): 588-631.
21. Godlewski G, Kunos G. Overview of nonclassical cannabinoid receptors. In: Abood ME, Sorensen RG, Stella N, editors. Endocannabinoids: Actions at Non-CB1/CB2 Cannabinoid Receptors. New York: Springer; 2013:3-27.
22. Marzo V, Petrocellis L. Temperature-sensitive transient receptor potential channels as ionotropic cannabinoid receptors. In: Abood ME, Sorensen RG, Stella N, editors. Endocannabinoids: Actions at Non-CB1/CB2 Cannabinoid Receptors. New York: Springer; 2013:175-197.
23. Oddi S, Fezza F, Pasquariello N, etal. Evidence for the intracellular accumulation of anandamide in adiposomes. Cell Mol Life Sci. 2008;65(5):840-850.
24. Rodríguez De Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol. 2005;40(1):2-14.
25. De Petrocellis L, Melck D, Palmisano A, etal. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A. 1998;95(14):8375-8380.
26. Fonseca BM, Costa MA, Almada M, Correia-da-Silva G, Teixeira NA. Endogenous cannabinoids revisited: a biochemistry perspective. Prostaglandins Other Lipid Mediat. 2013;102-103:13-30.
27. Ueda N, Puffenbarger RA, Yamamoto S, Deutsch DG. The fatty acid amide hydrolase (FAAH). Chem Phys Lipids. 2000;108(1-2):107-121.
28. Gulyas AI, Cravatt BF, Bracey MH, etal. Segregation of two endocannabinoid-hydrolyzing enzymes into pre-and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci. 2004;20(2):441-458.
29. Woo AY, Wang TB, Zeng X, etal. Stereochemistry of an agonist determines coupling preference of β2-adrenoceptor to different G proteins in cardiomyocytes. Mol Pharmacol. 2009;75(1):158-165.
30. Glass M, Northup JK. Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 1999;56(6): 1362-1369.
31. Turu G, Hunyady L. Signal transduction of the CB1 cannabinoid receptor. J Mol Endocrinol. 2010;44(2):75-85.
32. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology. 2004;47 Suppl 1:345-358.
33. Abood ME, Martin BR. Neurobiology of marijuana abuse. Trends Pharmacol Sci. 1992;13(5):201-206.
34. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther. 2002;95(2):127-135.
35. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83(3):1017-1066.
36. Breivogel CS, Childers SR. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis. 1998;5(6 Pt B):417-431.
37. Patel S, Hillard CJ. Cannabinoid CB1 receptor agonists produce cerebellar dysfunction in mice. J Pharmacol Exp Ther. 2001;297(2): 629-637.
38. Pertwee RG, Wickens AP. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology. 1991;30(3):237-244.
39. Monory K, Blaudzun H, Massa F, etal. Genetic dissection of behavioural and autonomic effects of Δ9-tetrahydrocannabinol in mice. PLoS Biol. 2007;5(10):e269.
40. Turcotte D, Le Dorze JA, Esfahani F, Frost E, Gomori A, Namaka M. Examining the roles of cannabinoids in pain and other therapeutic indications: a review. Expert Opin Pharmacother. 2010;11(1):17-31.
41. Drew LJ, Harris J, Millns PJ, Kendall DA, Chapman V. Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPγS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur J Neurosci. 2000;12(6):2079-2086.
42. Hohmann AG, Briley EM, Herkenham M. Pre-and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res. 1999;822(1-2):17-25.
43. Klein TW, Newton C, Larsen K, etal. The cannabinoid system and immune modulation. J Leukoc Biol. 2003;74(4):486-496.
44. Ashton JC. The use of knockout mice to test the specificity of antibodies for cannabinoid receptors. Hippocampus. 2012;22(3):643-644.
45. Borner C, Hollt V, Kraus J. Activation of human T cells induces upregulation of cannabinoid receptor type 1 transcription. Neuroimmunomodulation. 2007;14(6):281-286.
46. Galiègue S, Mary S, Marchand J, etal. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232(1):54-61.
47. Klein TW, Lane B, Newton CA, Friedman H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med. 2000;225(1):1-8.
48. Tanasescu R, Constantinescu CS. Cannabinoids and the immune system: an overview. Immunobiology. 2010;215(8):588-597.
49. Pisanti S, Malfitano AM, Grimaldi C, etal. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. Best Pract Res Clin Endocrinol Metab. 2009;23(1):117-131.
50. Bowles DW, O'Bryant CL, Camidge DR, Jimeno A. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol. 2012;83(1):1-10.
51. Todaro B. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Comp Canc Netw. 2012;10(4):487-492.
52. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids. J Natl Cancer Inst. 1975;55(3): 597-602.
53. Sarfaraz S, Afaq F, Adhami VM, Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 2005;65(5):1635-1641.
54. Qamri Z, Preet A, Nasser MW, etal. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther. 2009;8(11):3117-3129.
55. Bouaboula M, Rinaldi M, Carayon P, etal. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem. 1993;214(1): 173-180.
56. Blázquez C, Carracedo A, Barrado L, etal. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 2006;20(14): 2633-2635.
57. Wang D, Wang H, Ning W, Backlund MG, Dey SK, DuBois RN. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res. 2008;68(15):6468-6476.
58. Xu X, Liu Y, Huang S, etal. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet. 2006;171(1):31-38.
59. Sarnataro D, Pisanti S, Santoro A, etal. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol. 2006;70(4):1298-1306.
60. Wasik AM, Christensson B, Sander B. The role of cannabinoid receptors and the endocannabinoid system in mantle cell lymphoma and other non-Hodgkin lymphomas. Semin Cancer Biol. 2011;21(5):313-321.
61. Sánchez C, de Ceballos ML, Gomez del Pulgar T, etal. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res. 2001;61(15):5784-5789.
62. McKallip RJ, Nagarkatti M, Nagarkatti PS. Δ-9-Tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol. 2005;174(6):3281-3289.
63. Rinaldi-Carmona M, Le Duigou A, Oustric D, etal. Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J Pharmacol Exp Ther. 1998;287(3):1038-1047.
64. Leterrier C, Bonnard D, Carrel D, Rossier J, Lenkei Z. Constitutive endocytic cycle of the CB1 cannabinoid receptor. J Biol Chem. 2004;279(34):36013-36021.
65. Castaneda J, Harui A, Kiertscher S, Roth J, Roth M. Differential expression of intracellular and extracellular CB2 cannabinoid receptor protein by human peripheral blood leukocytes. J Neuroimmune Pharmacol. 2013;8(1):323-332.
66. Bifulco M, Laezza C, Pisanti S, Gazzerro P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol. 2006;148(2): 123-135.
67. Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol. 2013;75(2):303-312.
68. Guindon J, Hohmann AG. The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol. 2011;163(7):1447-1463.
69. Caffarel MM, Andradas C, Pérez-Gómez E, Guzmán M, Sánchez C. Cannabinoids: a new hope for breast cancer therapy? Cancer Treat Rev. 2012;38(7):911-918.
70. Takeda S, Yamamoto I, Watanabe K. Modulation of Δ9-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase. Toxicology. 2009;259(1-2):25-32.
71. McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY. Cannabidiol as a novel inhibitor of Id-1gene expression in aggressive breast cancer cells. Mol Cancer Ther. 2007;6(11):2921-2927.
72. Von Bueren AO, Schlumpf M, Lichtensteiger W. Delta(9)-tetrahydrocannabinol inhibits 17β-estradiol-induced proliferation and fails to activate androgen and estrogen receptors in MCF7 human breast cancer cells. Anticancer Res. 2008;28(1A):85-89.
73. Caffarel MM, Andradas C, Mira E, etal. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer. 2010;9:196.
74. Sánchez MG, Ruiz-Llorente L, Sánchez AM, Díaz-Laviada I. Activation of phosphoinositide 3-kinase/PKB pathway by CB1 and CB2 cannabinoid receptors expressed in prostate PC-3cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal. 2003;15(9): 851-859.
75. Sánchez MG, Sánchez AM, Ruiz-Llorente L, Díaz-Laviada I. Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Lett. 2003;555(3): 561-566.
76. Mimeault M, Pommery N, Wattez N, Bailly C, Hénichart JP. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate. 2003;56(1):1-12.
77. Nithipatikom K, Isbell MA, Endsley MP, Woodliff JE, Campbell WB. Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells. Prostaglandins Other Lipid Mediat. 2011;94(1-2):34-43.
78. Jacobsson SOP, Rongård E, Stridh M, Tiger G, Fowler CJ. Serum-dependent effects of tamoxifen and cannabinoids upon C6glioma cell viability. Biochem Pharmacol. 2000;60(12):1807-1813.
79. McAllister S, Chan C, Taft R, etal. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol. 2005;74(1):31-40.
80. Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther. 2004;308(3):838-845.
81. Jacobsson SOP, Wallin T, Fowler CJ. Inhibition of rat C6glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther. 2001;299(3):951-959.
82. Carracedo A, Gironella M, Lorente M, etal. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 2006;66(13):6748-6755.
83. McKallip RJ, Lombard C, Fisher M, etal. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. 2002;100(2):627-634.
84. Herrera B, Carracedo A, Diez-Zaera M, Gómez del Pulgar T, Guzmán M, Velasco G. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Exp Cell Res. 2006;312(11):2121-2131.
85. Jia W, Hegde VL, Singh NP, etal. Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. Mol Cancer Res. 2006;4(8):549-562.
86. McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M. Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol. 2006;70(3):897-908.
87. Lombard C, Nagarkatti M, Nagarkatti PS. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk Res. 2005;29(8):915-922.
88. Herrera B, Carracedo A, Diez-Zaera M, Guzmán M, Velasco G. p38 MAPK is involved in CB2 receptor induced apoptosis of human leukaemia cells. FEBS Lett. 2005;579(22):5084-5088.
89. Flygare J, Gustafsson K, Kimby E, Christensson B, Sander B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett. 2005;579(30):6885-6889.
90. Gustafsson K, Wang X, Severa D, etal. Expression of cannabinoid receptors type 1 and type 2in non-Hodgkin lymphoma: growth inhibition by receptor activation. Int J Cancer. 2008;123(5):1025-1033.
91. Hart S, Fischer OM, Ullrich A. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 2004;64(6):1943-1950.
92. Barsky SH, Roth MD, Kleerup EC, Simmons M, Tashkin DP. Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. J Natl Cancer Inst. 1998;90(16):1198-1205.
93. Roth MD, Marques-Magallanes JA, Yuan M, Sun W, Tashkin DP, Hankinson O. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and 9-tetrahydrocannabinol. Am J Respir Cell Mol Biol. 2001;24(3):339-344.
94. Marcus DM, Jani AB, Rossi PJ. Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer. 2013; 119(6):1284.
95. D'Souza G, Palefsky JM, Zhong Y, etal. Marijuana use is not associated with cervical human papillomavirus natural history or cervical neoplasia in HIV-seropositive or HIV-seronegative women. Cancer Epidemiol Biomarkers Prev. 2010;19(3):869-872.
96. Liang C, McClean MD, Marsit C, etal. A population-based case-control study of marijuana use and head and neck squamous cell carcinoma. Cancer Prev Res (Phila). 2009;2(8):759-768.
97. Nithipatikom K, Endsley MP, Isbell MA, etal. 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res. 2004;64(24):8826-8830.
98. Ellert-Miklaszewska A, Kaminska B, Konarska L. Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal. 2005;17(1):25-37.
99. Casanova ML, Blázquez C, Martínez-Palacio J, etal. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest. 2003;111(1):43-50.
100. Gustafsson K, Christensson B, Sander B, Flygare J. Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Mol Pharmacol. 2006;70(5): 1612-1620.
101. Fernández-Ruiz J, Romero J, Velasco G, Tolón RM, Ramos JA, Guzmán M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci. 2007;28(1):39-45.
102. Ellert-Miklaszewska A, Grajkowska W, Gabrusiewicz K, Kaminska B, Konarska L. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res. 2007; 1137(1):161-169.
103. Blázquez C, Casanova ML, Planas A, etal. Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 2003;17(3):529-531.
104. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9(2):139-150.
105. Morad SAF, Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer. 2013;13(1):51-65.
106. Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Izquierdo M, Guzmán M. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med. 2000;6(3):313-319.
107. Williams TM, Medina F, Badano I, etal. Caveolin-1gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo: role of Cav-1in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem. 2004;279(49): 51630-51646.
108. Sloan EK, Stanley KL, Anderson RL. Caveolin-1inhibits breast cancer growth and metastasis. Oncogene. 2004;23(47):7893-7897.
109. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer. 2002;2(8):594-604.
110. Downer EJ, Gowran A, Murphy AC, Campbell VA. The tumour suppressor protein, p53, is involved in the activation of the apoptotic cascade by Δ9-tetrahydrocannabinol in cultured cortical neurons. Eur J Pharmacol. 2007;564(1-3):57-65.
111. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444.
112. Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther. 2011;10(7):1161-1172.
113. Gómez del Pulgar T, Velasco G, Sánchez C, Haro A, Guzmán M. De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J. 2002;363(Pt 1):183-188.
114. Salazar M, Lorente M, García-Taboada E, etal. The pseudokinase tribbles homologue-3 plays a crucial role in cannabinoid anticancer action. Biochim Biophys Acta. Epub April 6, 2013.
115. Salazar M, Carracedo A, Salanueva IJ, etal. TRB3 links ER stress to autophagy in cannabinoid antitumoral action. Autophagy. 2009;5(7):1048-1049.
116. Pineiro R, Maffucci T, Falasca M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene. 2011;30(2):142-152.
117. Bifulco M, Malfitano AM, Pisanti S, Laezza C. Endocannabinoids in endocrine and related tumours. Endocr Relat Cancer. 2008;15(2): 391-408.
118. Murphy LL, Muñoz RM, Adrian BA, etal. Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis. 1998;5(6):432-446.
119. de Miguel R, Romero J, Muñoz RM, etal. Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic γ-aminobutyric acid (GABA) inputs. Biochem Pharmacol. 1998;56(10):1331-1338.
120. Dewey WL, Peng TC, Harris LS. The effect of 1-trans-Δ9-tetrahydrocannabinol on the hypothalamo-hypophyseal-adrenal axis of rats. Eur J Pharmacol. 1970;12(3):382-384.
121. Pagotto U, Marsicano G, Fezza F, etal. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab. 2001;86(6):2687-2696.
122. Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev. 1993;15(1):48-65.
123. Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci. 2006;63(17): 2057-2066.
124. Hermanson D, Marnett L. Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev. 2011;30(3-4):599-612.
125. Joseph J, Niggemann B, Zaenker K, Entschladen F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother. 2004;53(8):723-728.
126. Rudolph MI, Boza Y, Yefi R, etal. The influence of mast cell mediators on migration of SW756 cervical carcinoma cells. J Pharmacol Sci. 2008;106(2):208-218.
127. Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol. 2005;144(8):1032-1036.
128. Grimaldi C, Pisanti S, Laezza C, etal. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res. 2006;312(4): 363-373.
129. Zhou D, Song ZH. CB1 cannabinoid receptor-mediated tyrosine phosphorylation of focal adhesion kinase-related non-kinase. FEBS Lett. 2002;525(1-3):164-168.
130. Curran NM, Griffin BD, O'Toole D, Brady KJ, Fitzgerald SN, Moynagh PN. The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1signaling pathway in human astrocytes in a cannabinoid receptor-independent manner. J Biol Chem. 2005;280(43): 35797-35806.
131. Khokha R, Waterhouse P, Yagel S, etal. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science. 1989;243(4893):947-950.
132. Zacchigna S, Zentilin L, Morini M, etal. AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther. 2004;11(1): 73-80.
133. Ramer R, Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst. 2008;100(1):59-69.
134. Blázquez C, Carracedo A, Salazar M, etal. Down-regulation of tissue inhibitor of metalloproteinases-1in gliomas: a new marker of cannabinoid antitumoral activity? Neuropharmacology. 2008;54(1):235-243.
135. Ligresti A, Moriello AS, Starowicz K, etal. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther. 2006;318(3):1375-1387.
136. Preet A, Ganju RK, Groopman JE. [Delta]9-tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene. 2007;27(3):339-346.
137. Pisanti S, Borselli C, Oliviero O, Laezza C, Gazzerro P, Bifulco M. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol. 2007; 211(2):495-503.
138. Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J. 2003;17(12):1771-1773.
139. Blázquez C, González-Feria L, Álvarez L, Haro A, Casanova ML, Guzmán M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res. 2004;64(16):5617-5623.
140. Thapa D, Lee JS, Heo SW, etal. Novel hexahydrocannabinol analogs as potential anti-cancer agents inhibit cell proliferation and tumor angiogenesis. Eur J Pharmacol. 2011;650(1):64-71.